---
document_datetime: 2023-09-21 17:13:04
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/teslascan-epar-procedural-steps-taken-authorisation_en.pdf
document_name: teslascan-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3899738
conversion_datetime: 2025-12-30 10:45:28.974101
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

<!-- image -->

Medicinal product no longer authorise The  company  Nycomed  Imaging  AS,  submitted  on  28  June  1996  to  the  European  Agency  for  the Evaluation of Medicinal Products (EMEA) an application for marketing authorisation of the medicinal product  Teslascan  (mangafodipir).  After  agreement  at  the  CPMP  meeting  16-18  January  1996  this medicinal product was referred to Part B of the Annex of the Council Regulation (EEC) 2309/93, of the 22 July 1993. The Rapporteur and Co-Rapporteur appointed by the CPMP were as follows: Rapporteur: Dr. M. Teeling Co-Rapporteur: Dr. W.F. van der Giesen Licensing status An NDA (NDA 20-652) was submitted in the USA on 8 September 1995. 2. Steps taken for the assessment of the product · A  request  for  the  re-inspection  of  the  finished  product-manufacturing  site  in  the  USA  was agreed  during  the  September  1996  CPMP  meeting,  to  be  performed  by  the  Norwegian  and Belgian  Inspectorates.  The  Norwegian  Board  of  Health  between  17-18  January  1996  had originally inspected the site. · The assessment report of the Co-Rapporteur was circulated to all members of the CPMP on 25 September 1996. · The draft assessment of the Rapporteur was circulated to all members of the CPMP on 30 September 1996. · During the November 1996 CPMP meeting, a consolidated list of questions was agreed upon which was sent to the applicant on 20 November 1996. · The applicant submitted the responses to the consolidated list of questions on 4 December 1996. · The  joint  rapporteur/co-rapporteur  assessment  of  the  responses  was  circulated  to  all  CPMP members on 17 January 1997. · The  re-inspection  of  the  finished  product  manufacturing  facilities  took  place  between  18-20 December 1996. · The applicant signed a letter of undertaking on follow-up measures on 17 February 1997. · The CPMP on the basis of the favorable benefit-risk assessment issued a positive opinion for granting a marketing authorisation to Teslascan solution for infusion on 18 February 1997.